Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other financing activities (2016 - 2022)

Syndax Pharmaceuticals (SNDX) has disclosed Other financing activities for 8 consecutive years, with $92000.0 as the latest value for Q1 2022.

  • For Q1 2022, Other financing activities rose 16.46% year-over-year to $92000.0; the TTM value through Mar 2022 reached $13000.0, down 18.75%, while the annual FY2020 figure was $1000.0, 99.45% down from the prior year.
  • Other financing activities hit $92000.0 in Q1 2022 for Syndax Pharmaceuticals, up from -$242000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $207000.0 in Q4 2018 and bottomed at -$242000.0 in Q4 2020.
  • Average Other financing activities over 5 years is $35941.2, with a median of $63000.0 recorded in 2018.
  • Year-over-year, Other financing activities skyrocketed 3500.0% in 2018 and then crashed 524.56% in 2020.
  • Syndax Pharmaceuticals' Other financing activities stood at $207000.0 in 2018, then crashed by 72.46% to $57000.0 in 2019, then plummeted by 524.56% to -$242000.0 in 2020, then changed by 0.0% to -$242000.0 in 2021, then surged by 138.02% to $92000.0 in 2022.
  • According to Business Quant data, Other financing activities over the past three periods came in at $92000.0, -$242000.0, and $99000.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.